2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Profiling, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Pharmacology, Adverse Events, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Diseases, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, ALL, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Study Population, Human, Adult, Animal Model
PAPER

4088 Histomorphology and single-cell transcriptome of chronic alloimmune-mediated lung injury after bone marrow and lung transplantation in mice

Yueyang Zhong, Jin Zhao2, Kaibo Yang3, Qifa Liu, MD4, Xuan Li, PhD5, Jingyu Chen6, Ruoyang Shao, MD, PhD7
1 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
2 Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
3 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
4 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
5 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
6 Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
7 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Pulmonary chronic graft-versus-host disease (pcGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) and chronic lung allograft dysfunction (CLAD) after lung transplantation (LTx) are major obstacles to long-term survival. Despite opposite directions of alloimmune injury, they share clinical and histopathological features, supporting the concept of chronic alloimmune-mediated lung injury (CAI-LI) and subsequent fibrotic remodeling as a shared immunopathology. However, human samples represent only a late stage of disease, leaving the natural evolution of both diseases unclear.

To explore the natural evolution of CAI-LI across multiple postoperative time points while minimizing clinical confounders, we established murine BMT (bone marrow transplantation) and LTx models. In the BMT model, B10.BR mice received T-cell-depleted C57BL/6 bone marrow alone (BMA) or together with splenocytes (BM/SP). LTx models included syngeneic (SYN-LTx, C57BL/6 to C57BL/6), MHC-mismatched (Ma-LTx, B10.BR to C57BL/6), and mHA-mismatched (Mi-LTx, C57BL/10 to C57BL/6) groups. Lungs were assessed by H&E and Masson staining with semi-quantitative scoring, multiplex immunofluorescence, and single-cell RNA sequencing (scRNA-seq).

BM/SP exhibited alveolar and interstitial inflammatory infiltration at D14 with fibrotic features worsening progressively up to D60, whereas BMA showed no obvious injury. Ma-LTx instead developed severe early acute cellular rejection (ACR) from D3 to D7, while Mi-LTx recapitulated the key histological features of human LTx-CLAD. Peri-airway and parenchymal fibrosis scores were comparable between BM/SP and Mi-LTx at D30, while pleural fibrosis and lymphoid aggregates were more prominent in Mi-LTx, indicating that BMT-pcGVHD and LTx-CLAD share core CAI-LI and fibrotic features despite different transplant settings and strain combinations.

Single-cell analysis revealed substantial immune-cell heterogeneity and classified macrophages into 10 subclusters: 4 alveolar (AM), 3 interstitial (IM), and 3 monocyte-derived (MDM) subsets. Pseudotime analysis showed that monocytes transitioned through MDM_Arg1 before diverging toward alveolar and interstitial macrophage lineages. Consistently, MDM_Arg1 predominated during the early stage of BMT-induced CAI-LI and peaked at D14, showing enhanced M1-like, leukocyte-migration, and inflammatory-response programs. Also, MDM_Arg1 exhibited increased outgoing signaling to mesenchymal and CD8+ T cells through IL1, MHC-I, and CD86 pathways, identifying it as an early pro-inflammatory signaling hub.

By day 30, AM_Trem2 and IM_Isg15 accumulated in BM/SP and Mi-LTx and localized to late-intermediate trajectory states, reflecting a transition from acute inflammation toward tissue remodeling and collagen biosynthesis. Although shared across models, these subsets displayed transplant context dependent programs, with stronger antigen presentation activity in BMT and enhanced inflammatory in LT. Fibroblasts transitioned from acute-injury responses toward profibrotic programs, accompanied by increased macrophage-fibroblast communication through TGF-β, SPP1, and IFN-I signaling, as inferred by cell communication analysis. In addition, CD8_Activated_Teff cells were the predominant recipients of macrophage-derived signals. Their interactions with macrophages involving antigen presentation, cell adhesion, co-stimulation/co-inhibition, and cytokine/chemokine signaling were significantly enhanced in disease groups, with CXCL, SPP1, and PD-L1 signaling shared across all disease conditions.

These findings were then validated in human samples. In public datasets, macrophage populations transcriptionally similar to AM_Trem2 and IM_Isg15 were enriched in CLAD, while an AM_Trem2-like population was also increased in cGVHD. Multiplex immunofluorescence of patient lungs demonstrated increased CD68+TREM2+ and CD68+ISG15+ macrophages in pcGVHD and CLAD, predominantly within peri-airway and parenchymal fibrotic regions.

In conclusion, our study reveals potential similarities in the immunopathology of CAI-LI arising from pcGVHD and CLAD, thereby providing resources and candidates for further mechanistic and functional validation.

Yueyang Zhong: No relevant conflicts of interest to declare.